AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05212987
Drug: FCN-098
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
Trial: NCT05155254
Drug: IO102-IO103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
Trial: NCT04583280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
Trial: NCT04661540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
Trial: NCT05241106
Drug: HYML-122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
Trial: NCT05048160
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
Trial: NCT05491785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
Trial: NCT06236178
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 40 mg methylprednisolone acetate
Trial: NCT06236178
Drug: Autologous Blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of autologous venous blood
Trial: NCT06236178
Drug: Local Anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 2% prilocaine HCl
Trial: NCT06248086
Drug: ASP2802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT06800313
Drug: HLD-0915
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Trial: NCT05642949
Drug: MHB036C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
Trial: NCT04619862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm descriptions
Trial: NCT06128252
Drug: XELOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin + capecitabine
Trial: NCT06337032
Drug: F/TAF (High Dose Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/25 mg fixed-dose combination (FDC) tablet administered orally
Trial: NCT06337032
Drug: F/TAF (Low Dose Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/10 mg FDC tablet administered orally
Trial: NCT06337032
Drug: F/TAF (Lowest Dose Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120/15 mg FDC tablet administered orally
Trial: NCT06337032
Drug: F/TAF (High Dose TOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60/7.5 mg tablet for oral suspension (TOS) administered orally
Trial: NCT06337032
Drug: F/TAF (Low Dose TOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30/3.75 mg TOS administered orally
Trial: NCT06337032
Drug: F/TAF (Lowest Dose TOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15/1.88 mg TOS administered orally
Trial: NCT06337032
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg tablet administered orally
Trial: NCT06337032
Drug: E/C/F/TAF (Low Dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/90/120/6 mg tablet administered orally
Trial: NCT06337032
Drug: B/F/TAF (High Dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablet administered orally
Trial: NCT06337032
Drug: B/F/TAF (Lowest Dose TOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.76/15/1.88 mg TOS administered orally
Trial: NCT06337032
Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
Trial: NCT06337032
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to the prescribing information
Trial: NCT06212583
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All ADT is provided as best prescribed for patient per their medical oncologist.
Trial: NCT04069052
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
Trial: NCT04069052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room air (placebo) flowed into a mask and breathed in.
Trial: NCT04944953
Drug: Botulinum toxin type A injection [HG-102]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration, Day 0, 20 units
Trial: NCT05203692
Drug: DS-7011a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous or subcutaneous administration, single dose
Trial: NCT05203692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous or subcutaneous administration, single dose
Trial: NCT05002140
Drug: XRD-0394
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose
Trial: NCT04914546
Drug: LY3819469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04914546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05633147
Drug: Drug drug interaction (DDI) - Clarithromycin (Part I)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
Trial: NCT06496997
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone at an equivalent dose of 350 mg/day
Trial: NCT05698407
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
Trial: NCT04757337
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 x 3-week cycles corresponding to a maximal duration of 18 weeks
Trial: NCT04757337
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Until progression up to 24 months
Trial: NCT04673864
Drug: D012, D326, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04786600
Drug: pre-specified sequence of FDA-approved drugs and drug combinations
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
Trial: NCT04676737
Drug: TTHX1114(NM141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTHX1114
Trial: NCT05753956
Drug: 5 Methoxy N,N Dimethyltryptamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH002 administered via i.v. bolus injection(s)
Trial: NCT05753956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH002 placebo administered via i.v. bolus injection
Trial: NCT06767969
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophenl 500mg (500mg/50ml) was infused intravenously every 6 hours( a single infusion is completed within 15-30 minutes) from the beginning of endovascular treatment to 48 hours after treatment.
Trial: NCT06769204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs of saline into the cervix and cervical canal 5 minutes before the procedure
Trial: NCT04792723
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synco (HK) oral aspirin 80mg tablet
Trial: NCT05702762
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/kg intramuscular injection
Trial: NCT05702762
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral antibiotic multi-day dosing based on local antibiogram
Trial: NCT06542237
Drug: YCT-529
RxNorm normalized name: YCT-529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Phase 1b part of the study, 4 dosing cohorts and one optional 5th cohort with 4 participants will be evaluated (up to 20 participants): 15, 45, 90 and 180 mg. In the Phase 2a part, up to 3 cohorts of up to 10 participants (up to 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion.
Trial: NCT06627556
Drug: H021 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H021 placebo oral tablet.
Trial: NCT05762458
Drug: Ammoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ammoxetine hydrochloride enteric-coated tablets
Trial: NCT05762458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to Ammoxetine.
Trial: NCT05991362
Drug: GFH312 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive single dose of GFH312 100 mg orally
Trial: NCT05991362
Drug: GFH312 120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days
Trial: NCT06112262
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison between heparin and hirudin
Trial: NCT04718051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
Trial: NCT05535920
Drug: LOKELMA 5 GM Powder for Oral Suspension
RxNorm normalized name: Lokelma 5 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
Trial: NCT05035953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone Dexborneol matching injection, addition to thrombolysis
Trial: NCT05065398
Drug: HLX208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450mg bid, take orally
Trial: NCT06348576
Drug: AD-209 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT06348576
Drug: AD-2091 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT06345404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soquelitinib matching placebo tablets
Trial: NCT05463575
Drug: Ketohexokinase inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
Trial: NCT00292760
Drug: Methyprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06433726
Drug: BY101921 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral PARP7 Inhibitor
Trial: NCT06332092
Drug: FID007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
Trial: NCT05626348
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Trial: NCT06462495
Drug: [18F]F-PSMA-N5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Trial: NCT05570539
Drug: BLU-5937 IR
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive two single and multiple administrations of Immediate Release reference formulation
Trial: NCT05570539
Drug: BLU-5937 ER
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive single and multiple oral administrations of Extended Release formulation
Trial: NCT04014712
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT06336993
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
Trial: NCT04806854
Drug: LUM-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT04922554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
Trial: NCT05141474
Drug: Non-myeloablative Lymphodepletion (NMA-LD) Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
Trial: NCT06660394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube
Trial: NCT06038084
Drug: Bronpass Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day
Trial: NCT06038084
Drug: Placebo of Erdos capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times a day (It is for the masking.)
Trial: NCT06038084
Drug: Placebo of Bronpass Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day (It is for the masking.)
Trial: NCT03946462
Drug: NO gas delivered during cardiac surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
Trial: NCT05907694
Drug: Optimal medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
Trial: NCT06433869
Drug: rmhTNF-NC
RxNorm normalized name: codeine phosphate / pseudoephedrine hydrochloride / triprolidine hydrochloride Oral Solution [Poly Hist NC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
Trial: NCT04712838
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A subjects were given oral F1 、F2 and F3 version SHR0302
Trial: NCT04712838
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B subjects were given oral F1 、F3 and F2 version SHR0302
Trial: NCT04712838
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C subjects were given oral F2 、F1 and F3 version SHR0302
Trial: NCT04712838
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D subjects were given oral F2 、F3 and F1 version SHR0302
Trial: NCT04712838
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E subjects were given oral F3 、F1 and F2 version SHR0302
Trial: NCT04712838
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group F subjects were given oral F3 、F2 and F1 version SHR0302
Trial: NCT04794998
Drug: Recommended treatment schedule
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
Trial: NCT05908513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar chemical structure of NAC but without function
Trial: NCT04980170
Drug: Clindamycin 300 mg
RxNorm normalized name: clindamycin 300 MG
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
Trial: NCT02386007
Drug: DW-3101_150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02386007
Drug: DW-3101_300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02386007
Drug: DW-3101_600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02386007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05665387
Drug: 0.1% STN1013600 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
Trial: NCT05665387
Drug: 0.3% STN1013600 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
Trial: NCT05665387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution 1 drop BID for 2 months
Trial: NCT04995354
Drug: Hydrogel
RxNorm normalized name: HYDROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-medicated self-healing hydrogel to be applied three times a day for 1 week
Trial: NCT04983264
Drug: GBT021601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and capsules which contain GBT021601 drug substance
Trial: NCT05212116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Matching Placebo for SDI-118 is mannitol in capsules.
Trial: NCT06461442
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
Trial: NCT05755854
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
Trial: NCT05755854
Drug: Zoredronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
Trial: NCT05657834
Drug: [14C]-TVB-2640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of TVB-2640 oral administration
Trial: NCT04794998
Drug: Control treatment schedule
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimens different from the recommended one according to family phisicians personal practice.
Trial: NCT05104125
Drug: ASC40 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg of ASC40 orally once daily for 12 weeks.
Trial: NCT05685550
Drug: Toposide capsules combined with anrotinib and Emvolizumab group
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
Trial: NCT06520683
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine.
Trial: NCT03822858
Drug: Intrathecal MSC-NP injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart.
Trial: NCT05104125
Drug: ASC40 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg of ASC40 orally once daily for 12 weeks.